AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21877678 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-assisted epithelial debridement
Number of subjects: 33
Study 19464166 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine monotherapy
Number of subjects: 0
Study 19464166 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and vinorelbine combination therapy
Number of subjects: 0
Study 19464166 — intervention group
Group type: COMPARATOR
Intervention: Oral vinorelbine added to capecitabine
Number of subjects: 0
Study 19464166 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine-vinorelbine combination
Number of subjects: 0
Study 17366762 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant extension to occlusal ART restorations
Number of subjects: 572
Study 17366762 — intervention group
Group type: COMPARATOR
Intervention: Sealant free extensions to occlusal amalgam restorations
Number of subjects: 572
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mCi (131)I
Number of subjects: 509
Study 15070929 — intervention group
Group type: COMPARATOR
Intervention: <25 mCi (131)I
Number of subjects: 509
Study 11766122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 31
Study 11766122 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 31
Study 9892889 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postpartum discharge
Number of subjects: 3231
Study 9892889 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge (not specified)
Number of subjects: 3231
Study 7811582 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastomer-coated prosthetic graft (Intervascular)
Number of subjects: 30
Study 7811582 — intervention group
Group type: COMPARATOR
Intervention: Knitted double-velour prosthesis (Meadow)
Number of subjects: 30
Study 7811582 — intervention group
Group type: COMPARATOR
Intervention: Knitted prosthesis (Bard-USCI)
Number of subjects: 30
Study 3528055 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous methotrexate-5-fluorouracil chemotherapy
Number of subjects: 79
Study 3528055 — intervention group
Group type: COMPARATOR
Intervention: 1-hour sequential methotrexate-5-fluorouracil chemotherapy
Number of subjects: 79
Study 3528055 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiation therapy after chemotherapy
Number of subjects: 79
Study 3528055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy responders treated with radiation
Number of subjects: 79
Study 3528055 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy nonresponders treated with radiation
Number of subjects: 79
Study 28432210 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention combining personalised feedback on home air quality, behavioural support and nicotine replacement therapy for temporary abstinence
Number of subjects: 0
Study 28432210 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 28432210 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 0
Study 26892583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss group
Number of subjects: 40
Study 26892583 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss and exercise training group
Number of subjects: 40
Study 26892583 — intervention group
Group type: COMPARATOR
Intervention: Exercise training group
Number of subjects: 40
Study 26892583 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 25519680 — intervention group
Group type: EXPERIMENTAL
Intervention: PXT3003 high dose (HD)
Number of subjects: 80
Study 25519680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 22471133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion-medication group (25 cases)
Number of subjects: 80
Study 22471133 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-medication group (25 cases)
Number of subjects: 80
Study 22471133 — intervention group
Group type: COMPARATOR
Intervention: Medication group (30 cases)
Number of subjects: 80
Study 20441458 — intervention group
Group type: EXPERIMENTAL
Intervention: Written emotional expression treatment
Number of subjects: 0
Study 20441458 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18513915 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotaped consultations (31 patients)
Number of subjects: 58
Study 18513915 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 58
Study 18679607 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidan Granule (LDG)
Number of subjects: 60
Study 18679607 — intervention group
Group type: COMPARATOR
Intervention: Sodium cholate
Number of subjects: 60
Study 18679607 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 60
Study 15197500 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-DOTATOC
Number of subjects: 5
Study 15197500 — intervention group
Group type: COMPARATOR
Intervention: (111)In-DOTATATE
Number of subjects: 5
Study 15197500 — intervention group
Group type: EXPERIMENTAL
Intervention: (111)In-DOTATOC and (111)In-DOTATATE
Number of subjects: 5
Study 11389498 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fever scenario (40 degrees C)
Number of subjects: 98
Study 11389498 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fever scenario (38.5 degrees C)
Number of subjects: 98
Study 9313058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered orally (25 to 50 mg/kg divided into 2 portions) for 14‐42 days
Number of subjects: 139
Study 9313058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin administered intravenously (10 to 23 mg/kg injected twice a day) for 14‐18 days
Number of subjects: 139
Study 9313058 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 139
Study 9313058 — intervention group
Group type: COMPARATOR
Intervention: Azlocillin
Number of subjects: 139
Study 8311697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (30 sessions)
Number of subjects: 111
Study 8311697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (20 sessions)
Number of subjects: 111
Study 8311697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (15 sessions)
Number of subjects: 111
Study 8311697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (10 sessions)
Number of subjects: 111
Study 8311697 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 111
Study 3743194 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution after induction of anaesthesia
Number of subjects: 44
Study 3743194 — intervention group
Group type: COMPARATOR
Intervention: No blood withdrawn (Control)
Number of subjects: 44
Study 31951913 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive uptake among women with unplanned pregnancies (UP)
Number of subjects: 807
Study 31951913 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive uptake among women with planned pregnancies (PP)
Number of subjects: 807
Study 31951913 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use at 3-month follow-up for UP group
Number of subjects: 807
Study 31951913 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive use at 3-month follow-up for PP group
Number of subjects: 807
Study 30732648 — intervention group
Group type: EXPERIMENTAL
Intervention: Var-HSA group (vaccine without human serum albumin)
Number of subjects: 1231
Study 30732648 — intervention group
Group type: COMPARATOR
Intervention: Var + HSA group (vaccine with human serum albumin)
Number of subjects: 1231
Study 30732648 — intervention group
Group type: EXPERIMENTAL
Intervention: Var-HSA group
Number of subjects: 1231
Study 30732648 — intervention group
Group type: COMPARATOR
Intervention: Var + HSA group
Number of subjects: 1231
Study 30732648 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1231
Study 28559014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (P)
Number of subjects: 113
Study 28559014 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus 5FU (PF)
Number of subjects: 113
Study 25618802 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weightbearing from day 1 of treatment
Number of subjects: 60
Study 25618802 — intervention group
Group type: COMPARATOR
Intervention: Non-weightbearing for 6 weeks
Number of subjects: 60
Study 24053153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexylaminolevulinate (HAL) photodynamic diagnosis (PDD)‐assisted transurethral resection of bladder tumour (TURBT) plus single‐shot intravesical mitomycin C
Number of subjects: 249
Study 24053153 — intervention group
Group type: COMPARATOR
Intervention: Conventional white-light‐assisted TURBT plus single‐shot intravesical mitomycin C
Number of subjects: 249
Study 24053153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexylaminolevulinate (HAL) photodynamic diagnosis (PDD)
Number of subjects: 249
Study 24053153 — intervention group
Group type: COMPARATOR
Intervention: Conventional white-light diagnosis
Number of subjects: 249
Study 21387176 — intervention group
Group type: EXPERIMENTAL
Intervention: +MSS
Number of subjects: 68
Study 21387176 — intervention group
Group type: COMPARATOR
Intervention: -MSS
Number of subjects: 68
Study 19708911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (2 microg x kg(‐1)) with hyperbaric bupivacaine
Number of subjects: 54
Study 19708911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) with hyperbaric bupivacaine
Number of subjects: 54
Study 17101710 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2-1.8 mg/kg per day (continued same dose)
Number of subjects: 229
Study 17101710 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg/kg per day (low dose)
Number of subjects: 229
Study 15894837 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (temocapril 1 mg + losartan 12.5 mg)
Number of subjects: 31
Study 15894837 — intervention group
Group type: COMPARATOR
Intervention: Temocapril 1 mg
Number of subjects: 31
Study 15894837 — intervention group
Group type: COMPARATOR
Intervention: Losartan 12.5 mg
Number of subjects: 31
Study 11379375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 38
Study 11379375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9407446 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic nephropathy in IDDM patients
Number of subjects: 0
Study 9407446 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 8506890 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized garlic powder tablets (300 mg three times a day)
Number of subjects: 42
Study 8506890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3554055 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal heart rate monitoring
Number of subjects: 246
Study 3554055 — intervention group
Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 246
Study 29536106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine Structure Processing (FSP) strategy
Number of subjects: 26
Study 29536106 — intervention group
Group type: EXPERIMENTAL
Intervention: FS4 strategy (low stimulation rate)
Number of subjects: 26
Study 29536106 — intervention group
Group type: COMPARATOR
Intervention: FS4 strategy (high stimulation rate)
Number of subjects: 26
Study 26442648 — intervention group
Group type: EXPERIMENTAL
Intervention: ABO-D matched RBC transfusions
Number of subjects: 853
Study 26442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended matched RBC transfusions
Number of subjects: 853
Study 26442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol analysis
Number of subjects: 853
Study 26442648 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis of patients receiving RBCs without PLT transfusions
Number of subjects: 853
Study 24286115 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart administered by InsuJet
Number of subjects: 10
Study 24286115 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart administered by FlexPen
Number of subjects: 10
Study 23037329 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk-like fabric linens
Number of subjects: 582
Study 23037329 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital linens
Number of subjects: 582
Study 19915206 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted minimal-lift environment (engineering, administrative, and behavioral controls)
Number of subjects: 0
Study 19915206 — intervention group
Group type: COMPARATOR
Intervention: Engineering controls only (comparison nursing unit)
Number of subjects: 0
Study 18695272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.1 mg/kg/dose) three times a day for 7 days
Number of subjects: 140
Study 18695272 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times a day for 7 days
Number of subjects: 140
Study 18695272 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.1 mg/kg/dose)
Number of subjects: 140
Study 18695272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 15920045 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 19
Study 15920045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 12127929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala‐Gln group received 0.972 g amino acids/kg/day and 0.417 g of L‐alanyl‐L‐glutamine (Ala‐Gln)/kg/day.
Number of subjects: 48
Study 12127929 — intervention group
Group type: COMPARATOR
Intervention: Control group (Conv) received 1.5 g amino acids/kg/day.
Number of subjects: 48
Study 12127929 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala‐Gln group
Number of subjects: 48
Study 12127929 — intervention group
Group type: COMPARATOR
Intervention: Conv group
Number of subjects: 48
Study 10219027 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification or trabeculectomy with shield on non-operated eye
Number of subjects: 60
Study 7781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia with IPPV (n = 71)
Number of subjects: 137
Study 7781634 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia with spontaneous breathing (n = 66)
Number of subjects: 137
Study 1697824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin administration
Number of subjects: 103
Study 1697824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 103
Study 668268 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of aqueous ethanol diluted to 25% administered orally
Number of subjects: 31
Study 668268 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 31
Study 668268 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration
Number of subjects: 31
Study 668268 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient of the blood alcohol curve
Number of subjects: 31
Study 30590412 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)-based therapy
Number of subjects: 42
Study 30590412 — intervention group
Group type: COMPARATOR
Intervention: Protease inhibitor (PI/r)-based therapy
Number of subjects: 42
Study 26659070 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat (40 E%) with 20 E% MUFA and low in glycemic index (MUFA)
Number of subjects: 131
Study 26659070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (25 E%) and medium in glycemic index (LF)
Number of subjects: 131
Study 26659070 — intervention group
Group type: COMPARATOR
Intervention: Control (35 E% fat) and high in glycemic index (CTR)
Number of subjects: 131
Study 26476332 — intervention group
Group type: EXPERIMENTAL
Intervention: iTBS over the prefrontal cortex
Number of subjects: 41
Study 26476332 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 41
Study 23375512 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 24-hour pain intensity recall rating
Number of subjects: 0
Study 23375512 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores made up of 2 to 9 different ratings
Number of subjects: 0
Study 23375512 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores made up of 1 to 9 24-hour pain intensity recall ratings
Number of subjects: 0
Study 20122814 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown diet (rich in Maillard reaction products)
Number of subjects: 20
Study 20122814 — intervention group
Group type: COMPARATOR
Intervention: White diet (poor in Maillard reaction products)
Number of subjects: 20
Study 19829702 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing and physiotherapy assessment, individually tailored exercise strategies, nurse home visits, and telephone follow-up for 24 weeks.
Number of subjects: 0
Study 19829702 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition (control group).
Number of subjects: 0
Study 16709215 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 20 mg daily
Number of subjects: 62
Study 16709215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 15645890 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% hydrogen-peroxide whitening strip
Number of subjects: 17
Study 15645890 — intervention group
Group type: COMPARATOR
Intervention: 6.5% hydrogen-peroxide whitening strip (positive control)
Number of subjects: 17
Study 15645890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strips
Number of subjects: 17
Study 11706099 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg IA r‐proUK over 120 minutes plus IV fixed‐dose heparin
Number of subjects: 180
Study 11706099 — intervention group
Group type: COMPARATOR
Intervention: IV fixed‐dose heparin alone
Number of subjects: 180
Study 11706099 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐proUK treatment
Number of subjects: 180
Study 9681371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 10 mg
Number of subjects: 6
Study 9681371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 20 mg
Number of subjects: 6
Study 9681371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 30 mg
Number of subjects: 6
Study 9681371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline 40 mg
Number of subjects: 6
Study 9681371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8027415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day haloperidol
Number of subjects: 55
Study 8027415 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day haloperidol
Number of subjects: 55
Study 8027415 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day haloperidol
Number of subjects: 55
Study 2553993 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with IFN-beta and IFN-gamma
Number of subjects: 37
Study 2553993 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 37
Study 1106935 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin solution in capsule form
Number of subjects: 0
Study 1106935 — intervention group
Group type: COMPARATOR
Intervention: Digoxin tablets with 97% dissolution rate
Number of subjects: 0
Study 1106935 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin formulations
Number of subjects: 0
Study 31601111 — intervention group
Group type: EXPERIMENTAL
Intervention: SBML
Number of subjects: 80
Study 31601111 — intervention group
Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 80
Study 30543665 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation embedded in music
Number of subjects: 18
Study 30543665 — intervention group
Group type: COMPARATOR
Intervention: Music alone (sham, control)
Number of subjects: 18
Study 27595956 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml 2% lidocaine
Number of subjects: 36
Study 27595956 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml 1% lidocaine
Number of subjects: 36
Study 24355668 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing intervention
Number of subjects: 91
Study 24355668 — intervention group
Group type: COMPARATOR
Intervention: Delayed-intervention control group
Number of subjects: 91
Study 22173280 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg alone
Number of subjects: 12
Study 22173280 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg co-administered with gemfibrozil 600 mg
Number of subjects: 12
Study 20848164 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam (0.04 mg/kg)
Number of subjects: 120
Study 20848164 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol (0.1 mg/kg)
Number of subjects: 120
Study 20848164 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 120
Study 17851194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0
Study 17851194 — intervention group
Group type: EXPERIMENTAL
Intervention: NICE appraisal of cholinesterase inhibitors
Number of subjects: 0
Study 16240563 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (six 12-oz cans of beer)
Number of subjects: 10
Study 16240563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (juice)
Number of subjects: 10
Study 12456899 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose 30% orally and placebo (Unguentum Merck) on the skin
Number of subjects: 201
Study 12456899 — intervention group
Group type: COMPARATOR
Intervention: EMLA on the skin and orally administered placebo (sterile water)
Number of subjects: 201